Furthermore, baseline serum IL-6 levels may influence the clinical response to this therapy, with lower IL-6 levels being associated with greater T-cell proliferation, cytokine production, and tumour-infiltrating T cells, leading to improved treatment outcomes [50]. This evidence concerns the gene IL6 and neoplasm.